Search for the best indicators for the presence of a VPS13B gene mutation and confirmation of diagnostic criteria in a series of 34 patients genotyped for suspected Cohen syndrome.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El Chehadeh Salima, Aral Bernard, Gigot Nadège, Thauvin-Robinet Christel, Donzel Anne, Delrue Marie-Ange, Lacombe Didier, David Albert, Burglen Lydie, Philip Nicole, Moncla Anne, Cormier-Daire Valérie, Rio Marlène, Edery Patrick, Verloes Alain, Bonneau Dominique, Afenjar Alexandra, Jacquette Aurélia, Heron Delphine, Sarda Pierre, Pinson Lucile, Doray Bérénice, Vigneron Jacqueline, Leheup Bruno, Frances-Guidet Anne-Marie, Dienne Gwenaelle, Holder Muriel, Masurel-Paulet Alice, Huet Frédéric, Teyssier Jean-Raymond, Faivre Laurence
Аннотация
PATIENTS AND METHODS: The aim of the study was to determine which of the above clinical features were the best indicators for the presence of VPS13B gene mutations in a series of 34 patients with suspected Cohen syndrome referred for molecular analysis of VPS13B.
RESULTS: 14 VPS13B gene mutations were identified in 12 patients, and no mutation was found in 22 patients. The presence of chorioretinal dystrophy (92% vs 32%, p=0.0023), intermittent neutropenia (92% vs 5%, p<0.001), and postnatal microcephaly (100% vs 48%, p=0.0045) was significantly higher in the group of patients with a VPS13B gene mutation compared to the group of patients without a mutation. All patients with VPS13B mutations had chorioretinal dystrophy and/or intermittent neutropenia. The Kolehmainen diagnostic criteria provided 100% sensibility and 77% specificity when applied to this series.
CONCLUSION: From this study and a review of more than 160 genotyped cases from the literature, it is concluded that, given the large size of the gene, VPS13B screening is not indicated in the absence of chorioretinal dystrophy or neutropenia in patients aged over 5 years. The follow-up of young patients could be a satisfactory alternative unless there are some reproductive issues.